Objective:We evaluated the incidence of psychiatric disorders inpatients with allergic rhinitis (AR) and assessed the effects of the use ofantidepressants on symptoms when they are included in the treatmentregimen of patients with AR who are resistant to AR treatment. Methods:A total of 49 patients who were resistant to the treatment forAR and who did not accept the option of immunotherapy were included in the study. Thirty-eight of the 40 patients were advised to take theantidepressant sertraline; however, only 21 of them agreed to use themedication while 17 of them refused. The 21 patients who agreed tobegin the antidepressant were also advised to undergo AR treatmentwith desloratadine once per day and intranasal mometasone furoate onceper day (Group 1). The patients who refused to use the antidepressantwere advised to begin the AR treatment (Group 2). Symptom scoring forAR was again performed for all patients 6 weeks after treatment. ThePsychological Symptom Checklist-90 (SCL-90), Beck DepressionInventory (BDI), and State-Trait Anxiety Inventory (STAI TX I and TXII) were performed on the patients in the company of a psychiatrist. Results: The post-treatment nasal and non-nasal symptom scores inGroup 1 were significantly better than the pretreatment scores for any ofthe seven symptoms (p=0.000). No significant correlation was foundbetween the AR symptom scores and the average SCL-90 general symptom score, the SCL-90 subscale scores, the total BDI scores, and the STAIscores (p>0.05). Conclusion:This study suggests that the use of antidepressants diminishes the allergic symptoms in patients with treatment-resistant AR since psychosomatic factor is of great importance in the patient population of AR.